Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Child Development Disorders, Pervasive

ClinicalTrials.gov lists 2,252 trials for Child Development Disorders, Pervasive or a narrower condition beneath it. National Institute of Mental Health (NIMH) has the most among industry and government lead sponsors, with 21.

MeSH D002659 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 93 Phase 1/2 Phase 1/2 35 Phase 2 Phase 2 208 Phase 2/3 Phase 2/3 26 Phase 3 Phase 3 69 Phase 4 Phase 4 38 Not applicable Not applicable 1,344 Observational Observational 437 Phase 1 Phase 1 93 Phase 1/2 Phase 1/2 35 Phase 2 Phase 2 208 Phase 2/3 Phase 2/3 26 Phase 3 Phase 3 69 Phase 4 Phase 4 38 Not applicable Not applicable 1,344 Observational Observational 437

Trials per phase (log scale)

2 more sections with rows

117 of the 2,252 trials are tagged with Child Development Disorders, Pervasive itself; the rest are tagged with a narrower condition beneath it.

Get the Child Development Disorders, Pervasive report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Child Development Disorders, Pervasive trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 211

1997: 2 trials (Observational 1, Phase 3 1) 1998: 2 trials (Not applicable 2) 1999: 5 trials (Observational 1, Phase 3 4) 2000: 3 trials (Observational 2, Not applicable 1) 2001: 6 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 1/2 1, Phase 1 1) 2002: 7 trials (Observational 1, Phase 3 2, Phase 2 4) 2003: 7 trials (Observational 1, Not applicable 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2004: 13 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2005: 19 trials (Observational 2, Not applicable 5, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2006: 32 trials (Observational 6, Not applicable 9, Phase 4 4, Phase 3 3, Phase 2 5, Phase 1/2 2, Phase 1 3) 2007: 32 trials (Observational 9, Not applicable 10, Phase 4 1, Phase 3 5, Phase 2 2, Phase 1 5) 2008: 35 trials (Observational 7, Not applicable 13, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 2) 2009: 53 trials (Observational 13, Not applicable 20, Phase 4 2, Phase 3 2, Phase 2/3 2, Phase 2 7, Phase 1/2 4, Phase 1 3) 2010: 53 trials (Observational 15, Not applicable 19, Phase 4 3, Phase 3 4, Phase 2/3 3, Phase 2 7, Phase 1 2) 2011: 46 trials (Observational 12, Not applicable 14, Phase 4 4, Phase 3 2, Phase 2 11, Phase 1 3) 2012: 58 trials (Observational 11, Not applicable 22, Phase 3 4, Phase 2/3 3, Phase 2 14, Phase 1/2 1, Phase 1 3) 2013: 74 trials (Observational 20, Not applicable 31, Phase 4 1, Phase 3 4, Phase 2 12, Phase 1 6) 2014: 77 trials (Observational 18, Not applicable 36, Phase 4 4, Phase 2/3 1, Phase 2 13, Phase 1/2 3, Phase 1 2) 2015: 101 trials (Observational 22, Not applicable 60, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 6, Phase 1/2 3, Phase 1 4) 2016: 99 trials (Observational 14, Not applicable 56, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 11) 2017: 74 trials (Observational 15, Not applicable 43, Phase 4 2, Phase 3 2, Phase 2 6, Phase 1/2 1, Phase 1 5) 2018: 116 trials (Observational 26, Not applicable 64, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 3) 2019: 124 trials (Observational 21, Not applicable 79, Phase 4 2, Phase 3 2, Phase 2 10, Phase 1/2 2, Phase 1 8) 2020: 110 trials (Other 1, Observational 23, Not applicable 66, Phase 4 1, Phase 3 2, Phase 2 12, Phase 1/2 1, Phase 1 4) 2021: 150 trials (Observational 32, Not applicable 100, Phase 4 1, Phase 3 3, Phase 2 9, Phase 1/2 1, Phase 1 4) 2022: 160 trials (Observational 26, Not applicable 115, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1 6) 2023: 204 trials (Observational 34, Not applicable 148, Phase 4 1, Phase 3 2, Phase 2/3 3, Phase 2 13, Phase 1 3) 2024: 211 trials (Observational 37, Not applicable 157, Phase 3 1, Phase 2/3 3, Phase 2 9, Phase 1/2 1, Phase 1 3) 2025: 176 trials (Observational 37, Not applicable 121, Phase 3 1, Phase 2 13, Phase 1/2 2, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 184
2025 176
2024 211
2023 204
2022 160
2021 150
2020 110
2019 124
2018 116
2017 74

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 220 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 253 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 1,322 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Child Development Disorders, Pervasive trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 93
Phase 1/2 35
Phase 2 208
Phase 2/3 26
Phase 3 69
Phase 4 38
Not applicable 1,344
Observational 437
Expanded access 1
Unknown 1

How many Child Development Disorders, Pervasive trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 133
Recruiting 354
Enrolling by invitation 40
Active, not recruiting 87
Completed 1,212

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Child Development Disorders, Pervasive trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Mental Health (NIMH) 21

Which drugs are being tested for Child Development Disorders, Pervasive? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Aripiprazole 19
Arbaclofen 10
SFX-01 7
Buspirone 7

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Treatment As Usual 36
IM Oxytocin 18
IR Risperidone 17
8IU intranasal oxytocin 11
Control (placebo) group 11

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Child Development Disorders, Pervasive trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Suicidal ideation 36 6
Schizophrenia 22 1
Suicide attempt 17 2
Aggression 15 7
Bipolar I disorder 12 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Child Development Disorders, Pervasive? (521)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Social visual attention as a treatment outcome: evaluating the social games for autistic adolescents (SAGA) intervention. Scientific reports 2024 Yes
Measuring Changes in Social Skills Throughout an Intervention Program for Children with ASD, Contributions from Polar Coordinate Analysis. Journal of autism and developmental disorders 2023 Yes
Tackling hypo and hyper sensory processing heterogeneity in autism: From clinical stratification to genetic pathways. Autism research : official journal of the International Society for Autism Research 2023 Yes
Preemptive interventions for infants and toddlers with a high likelihood for autism: A systematic review and meta-analysis. Autism : the international journal of research and practice 2022 Yes
The impact of using digitally-mediated social stories on the perceived competence and attitudes of parents and practitioners supporting children with autism. PloS one 2022 Yes

Showing 5 of 521 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Rare pervasive developmental disorder 168778 Exact Orphanet Rare Disease Ontology (ORDO)
Rare pervasive developmental disorder 168778 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages